Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation.

Pranab Maiti1, Jian Kong, So Ra Kim

  • 1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.

Biochemistry
|January 18, 2006
PubMed
Summary

New RPE65 antagonists prevent lipofuscin accumulation in retinal pigment epithelial cells, offering a potential treatment for Stargardt disease and related macular degenerations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual cycle-derived bisretinoids as endogenous natural products: enzyme-free formation, photochemical reactivity, and retinal degeneration.

Natural product reports·2026
Same author

Chromophore-loaded CRALBP restores rod visual cycle in chromophore-deficient mice.

Molecular therapy. Advances·2026
Same author

Disease mechanisms revealed in the P23H opsin knock-in mouse model of retinitis pigmentosa.

PNAS nexus·2026
Same author

More insights from Abca4<sup>-/-</sup> mouse models of recessive Stargardt disease.

The Journal of biological chemistry·2026
Same author

Tracking Systemic and Ocular Vitamin A.

Cells·2026
Same author

Novel Grm6 Variant in a no b-wave (nob) Mouse Model: Phenotype Characterization and Gene Therapy.

Investigative ophthalmology & visual science·2025

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Biochemistry

Background:

  • Lipofuscin accumulation in retinal pigment epithelial (RPE) cells causes blinding diseases like Stargardt disease.
  • This accumulation, including A2E, is linked to the visual cycle's byproducts.
  • Targeting the visual cycle is crucial for preventing retinotoxic lipofuscin formation.

Purpose of the Study:

  • Identify rate-limiting steps in the visual cycle to inhibit lipofuscin formation.
  • Investigate non-retinoid isoprenoid compounds as RPE65 antagonists.
  • Evaluate the therapeutic potential of RPE65 antagonists for macular degeneration.

Main Methods:

  • In vitro and in vivo experiments to test RPE65 antagonists.
  • Assessing the impact of antagonists on 11-cis-retinal regeneration.

Related Experiment Videos

  • Chronic treatment of a Stargardt disease mouse model to observe A2E formation.

    • Main Results:

    • Identified specific isoprenoid compounds as RPE65 antagonists.
    • Demonstrated that RPE65 antagonists block 11-cis-retinal regeneration, indicating RPE65 is rate-limiting.
    • Showed that RPE65 antagonists abolish A2E formation in a Stargardt mouse model.

    Conclusions:

    • RPE65 is a rate-limiting protein in the visual cycle and A2E formation pathway.
    • Nontoxic isoprenoid RPE65 antagonists are potential treatments for lipofuscin-related macular degeneration.
    • These antagonists can further elucidate RPE65's role in vision.